Accès gratuit
Med Sci (Paris)
Volume 28, Numéro 2, Février 2012
Page(s) 172 - 178
Section M/S Revues
Publié en ligne 27 février 2012
  1. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998 ; 92 : 3105–3114. [PubMed] [Google Scholar]
  2. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995 ; 332 : 201–208. [CrossRef] [PubMed] [Google Scholar]
  3. Martinez V. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005 ; 191 : 2053–2063. [CrossRef] [PubMed] [Google Scholar]
  4. Lefrere JJ, Morand-Joubert L, Mariotti M, et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997 ; 90 : 1133–1140. [PubMed] [Google Scholar]
  5. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005 ; 41 : 1053–1056. [CrossRef] [PubMed] [Google Scholar]
  6. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009 ; 200 : 1714–1723. [CrossRef] [PubMed] [Google Scholar]
  7. Martinez V, Autran B. Les HIV controllers : une nouvelle entité évolutive de l’infection par le VIH ? Med Sci (Paris) 2008 ; 24 : 7–9. [CrossRef] [EDP Sciences] [Google Scholar]
  8. Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. Aids 2009 ; 23 : 1163–1169. [CrossRef] [PubMed] [Google Scholar]
  9. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008 ; 197 : 563–571. [CrossRef] [PubMed] [Google Scholar]
  10. Boufassa F, Saez-Cirion A, Lechenadec J, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PloS One 2011 ; 6 : e18726. [CrossRef] [PubMed] [Google Scholar]
  11. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009 ; 200 : 984–290. [CrossRef] [PubMed] [Google Scholar]
  12. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). Aids 2007 ; 21 : 1043–1045. [CrossRef] [PubMed] [Google Scholar]
  13. Miura T, Brockman MA, Brumme CJ, et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 2008 ; 82 : 8422–8430. [CrossRef] [PubMed] [Google Scholar]
  14. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009 ; 83 : 329–335. [CrossRef] [PubMed] [Google Scholar]
  15. Miura T, Brockman MA, Brumme ZL, et al. HLA-associated alterations in replication capacity of chimeric NL4–3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2009 ; 83 : 140–149. [CrossRef] [PubMed] [Google Scholar]
  16. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 2011 ; 6 : 163–168. [CrossRef] [PubMed] [Google Scholar]
  17. Dalmasso C, Carpentier W, Meyer L, et al. Distinct genetic loci control plasma HIV-RNA, cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome wide association 01 study. PloS One 2008 ; 3 : e3907. [CrossRef] [PubMed] [Google Scholar]
  18. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007 ; 317 : 944–947. [CrossRef] [PubMed] [Google Scholar]
  19. Van Grevenynghe J, Procopio FA, He Z, et al. Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nat Med 2008 ; 14 : 266–274. [CrossRef] [PubMed] [Google Scholar]
  20. Vigneault F, Woods M, Buzon MJ, et al. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol 2011 ; 85 : 3015–3019. [CrossRef] [PubMed] [Google Scholar]
  21. Saez-Cirion A, Hamimi C, Bergamaschi A, et al. Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 2011 ; 118 : 955–964. [CrossRef] [PubMed] [Google Scholar]
  22. Chen H, Li C, Huang J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011 ; 121 : 1549–1560. [CrossRef] [PubMed] [Google Scholar]
  23. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 ; 12 : 1365–1371. [CrossRef] [PubMed] [Google Scholar]
  24. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008 ; 197 : 126–133. [CrossRef] [PubMed] [Google Scholar]
  25. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids 2006 ; 20 : 2275–2283. [CrossRef] [PubMed] [Google Scholar]
  26. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype Proc Natl Acad Sci USA 2007 ; 104 : 6776–6781. [CrossRef] [Google Scholar]
  27. Saez-Cirion A, Pancino G, Sinet M, et al. HIV controllers: how do they tame the virus?. Trends Immunol 2007 ; 28 : 532–540. [CrossRef] [PubMed] [Google Scholar]
  28. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006 ; 107 : 4781–4789. [CrossRef] [PubMed] [Google Scholar]
  29. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010 ; 6 : e1000917. [CrossRef] [PubMed] [Google Scholar]
  30. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002 ; 3 : 1061–1068. [CrossRef] [PubMed] [Google Scholar]
  31. Saez-Cirion A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009 ; 182 : 7828–7837. [CrossRef] [PubMed] [Google Scholar]
  32. Miura T, Brockman MA, Schneidewind A, et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte (corrected) recognition. J Virol 2009 ; 83 : 2743–2755. [CrossRef] [PubMed] [Google Scholar]
  33. Potter SJ, Lacabaratz C, Lambotte O, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007 ; 81 : 13904–13915. [CrossRef] [PubMed] [Google Scholar]
  34. Vingert B, Perez-Patrigeon S, Jeannin P, et al. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog 2011 ; 6 : e1000780. [CrossRef] [Google Scholar]
  35. O’Connell KA, Han Y, Williams TM, et al. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 2009 ; 83 : 5028–5034. [CrossRef] [PubMed] [Google Scholar]
  36. Vieillard V, Fausther-Bovendo H, Samri A, Debre P. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr 2011 ; 53 : 564–573. [Google Scholar]
  37. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids 2009 ; 23 : 897–906. [CrossRef] [PubMed] [Google Scholar]
  38. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005 ; 79 : 14169–14178. [CrossRef] [PubMed] [Google Scholar]
  39. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001 ; 410 : 980–987. [CrossRef] [PubMed] [Google Scholar]
  40. Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is “IV controller” status established? Clin Infect Dis 2009 ; 49 : 982–986. [CrossRef] [PubMed] [Google Scholar]
  41. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009 ; 113 : 3978–3989. [CrossRef] [PubMed] [Google Scholar]
  42. Cellerai C, Harari A, Stauss H, et al. Early, prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One 2011 ; 6 : e18164. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.